Cancer drugs that target specific types of poly ADP-ribose polymerase
RBN-3143 Clin1 atopic dermatitis; 3 undisclosed programs RD undisclosed
Ribon Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecules targeting stress support pathways in cancer and inflammation. The company's lead product candidate, RBN-2397, is a potent, selective, and orally available small molecule inhibitor of the monoPARP, PARP7, for the treatment of solid tumors. Ribon Therapeutics is also developing RBN-3143, a PARP14 inhibitor, for the treatment of solid tumors and hematologic malignancies.